Raltegravir with optimized background therapy for resistant HIV-1 infection.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  New England Journal of Medicine

• Publication date

  2008-07-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa0708975PMID 18650512
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Raltegravir With Optimized Background Therapy for Resistant HIV-1 Infection

  2009cited by this paper
• Treatment strategies for CML.

  2009cited by this paper
• Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

  2008cited by this paper
• Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

  2008cited by this paper
• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

  2007cited by this paper
• Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

  2007cited by this paper
• Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.

  2007cited by this paper
• Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

  2007cited by this paper
• Time Trends for HIV-1 Antiretroviral Resistance Among Antiretroviral-Experienced and Naive Pregnant Women in New York City During 1991 to Early 2001

  2007cited by this paper
• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

  2007cited by this paper
• Raltegravir: a new antiretroviral class for salvage therapy.

  2007cited by this paper
• No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.

  2007cited by this paper
• Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients

  2007cited by this paper
• Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study

  2007cited by this paper
• Cervical intraepithelial neoplasia associated with epidermodysplasia verruciformis HPV in an HIV-infected patient: a manifestation of immune restoration syndrome.

  2007cited by this paper
• Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

  2007cited by this paper
• Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

  2007cited by this paper
• Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients: 24-Week Results of POWER 3

  2007cited by this paper
• Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

  2007cited by this paper
• Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort.

  2006cited by this paper
• Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance

  2006cited by this paper
• Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy.

  2006cited by this paper
• Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

  2006cited by this paper
• Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance

  2006cited by this paper
• Non-Hodgkin's lymphoma as a rare manifestation of immune reconstitution disease in HIV-1 positive patients.

  2006cited by this paper
• Lung cancer as an immune reconstitution disease in an HIV-1 positive man receiving HAART.

  2006cited by this paper
• Cost-Effectiveness of Enfuvirtide in HIV Therapy for Treatment-Experienced Patients in the United States

  2006cited by this paper
• Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations

  2006cited by this paper
• Trends in Antiretroviral Drug Resistance and Clade Distributions Among HIV-1--Infected Blood Donors in Sao Paulo, Brazil

  2006cited by this paper
• Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.

  2006cited by this paper
• Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

  2006cited by this paper
• Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel

  2006cited by this paper
• Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load

  2006cited by this paper
• HIV transmission and primary drug resistance.

  2006cited by this paper
• Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

  2006cited by this paper
• Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients

  2006cited by this paper
• Effects of drug resistance on viral load in patients failing antiretroviral therapy

  2006cited by this paper
• Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults.

  2006cited by this paper
• Three-Class Antiretroviral Resistance in a Patient with Acute HIV-1 Infection

  2006cited by this paper
• Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.

  2006cited by this paper
• A historical sketch of the discovery and development of HIV-1 integrase inhibitors

  2006cited by this paper
• Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

  2006cited by this paper
• Emerging anti-HIV drugs

  2005cited by this paper
• Drug-Class-Wide Resistance to Antiretrovirals in HIV-Infected Patients Failing Therapy: Prevalence, Risk Factors and Virological Outcome

  2005cited by this paper
• Treatment strategies for highly treatment-experienced HIV-infected patients

  2005cited by this paper
• Emerging anti-HIV drugs.

  2005cited by this paper
• A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.

  2005cited by this paper
• The prevalence of antiretroviral drug resistance in the United States

  2004cited by this paper
• Immune reconstitution in HIV-infected patients.

  2004cited by this paper
• Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen.

  2004cited by this paper
• Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques

  2004cited by this paper
• Malignant Melanoma and HIV Infection – Aggressive Course despite Immune Reconstitution

  2004cited by this paper
• Treatment for adult HIV infection.

  2004cited by this paper
• Development of Anti‐Retroviral Resistance of HIV‐1 Infected Individuals on Therapy: Is it inevitable?

  2004cited by this paper
• New antiretroviral drugs.

  2003cited by this paper
• Immune reconstitution in HIV infection and its relationship to cancer.

  2003cited by this paper
• Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

  2003cited by this paper
• Immune Reconstitution Inflammatory Syndrome Mimicking Relapse of AIDS Related Lymphoma in Patients with HIV 1 Infection

  2003cited by this paper
• Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution

  2001cited by this paper
• Resistance Profiles to Antiretroviral Drugs in HIV-1 Drug-Naive Patients in Argentina

  2001cited by this paper
• The cost effectiveness of combination antiretroviral therapy for HIV disease.

  2001cited by this paper
• Impact of HIV Type 1 Drug Resistance Mutations and Phenotypic Resistance Profile on Virologic Response to Salvage Therapy

  2001cited by this paper
• Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

  2000cited by this paper
• HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.

  2000cited by this paper
• The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.

  2000cited by this paper
• Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.

  1999cited by this paper
• Costs of HIV medical care in the era of highly active antiretroviral therapy.

  1999cited by this paper
• Combination antiretroviral therapy and recent declines in AIDS incidence and mortality.

  1999cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

  1998cited by this paper
• Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.

  1998cited by this paper
• Treatment strategies.

  1990cited by this paper
• UvA-DARE (Digital Academic Repository) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

  year unknowncited by this paper

• Deep tobit model: an integrated framework for high-dimensional censored regression with variable selection

  2026cites this paper
• HIV Treatment Paradigm Shifts over the Past 40 Years

  2025cites this paper
• Highly efficient production of HIV-1AD8 gp120 in mammalian cells

  2025cites this paper
• Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study

  2025cites this paper
• Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada

  2025cites this paper
• Electrochemical removal of antiretroviral drug - raltegravir from aquatic media: Multivariate optimization, degradation studies and transformation products characterization.

  2024cites this paper
• Exposure to the antiretroviral drug dolutegravir impairs structure and neurogenesis in a forebrain organoid model of human embryonic cortical development

  2024cites this paper
• Heavily treatment-experienced patients with HIV: are new mechanisms of action enough?

  2024cites this paper
• Patient / Adherence-Related Factors ( see Adherence to the Continuum of Care )

  2023cites this paper
• The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review

  2023cites this paper
• Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir

  2023cites this paper
• Editorial to the Special Issue “Clinical Immunology in Italy, with Special Emphasis to Primary and Acquired Immunodeficiencies: A Commemorative Issue in Honor of Prof. Fernando Aiuti”

  2023cites this paper
• The Integrase: An Overview of a Key Player Enzyme in the Antiviral Scenario

  2023cites this paper
• Integrase inhibitors: current protagonists in antiretroviral therapy.

  2023cites this paper
• A systematic review and meta-analysis assessing antiretroviral therapy for treatment-experienced HIV adult patients using an optimized background therapy approach: is there evidence enough for a standardized third-line strategy?

  2022influential citation
• Development of Azaindole-Based Frameworks as Potential Antiviral Agents and Their Future Perspectives

  2022cites this paper
• Real-World Characterization of the Portuguese Population Living with HIV who Initiated Raltegravir Based-Regimens: The REALITY Study.

  2022cites this paper
• Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1.

  2022cites this paper
• Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine

  2022cites this paper
• Effects of raltegravir formulation change on medication adherence and medication errors.

  2022cites this paper
• Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens

  2022cites this paper
• Long-term follow-up of HIV-1 multidrug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: toward drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.

  2022cites this paper
• Patterns and prognosis of holding regimens for people living with HIV in Asian countries

  2022cites this paper
• Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance

  2022cites this paper
• Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting

  2022cites this paper
• Indirect Treatment Comparisons of Lenacapavir plus Optimized Background Regimen Versus Other Treatments for Multi-Drug Resistant HIV.

  2022cites this paper
• Integrase strand transfer inhibitors can simplify HIV treatment

  2021cites this paper
• Retrospective Review of Virologic and Immunologic Response in Treatment-Experienced Patients on Third-Line HIV Therapy in Lusaka, Zambia

  2021cites this paper
• Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study

  2021cites this paper
• Evaluating fostemsavir as a therapeutic option for patients with HIV

  2021cites this paper
• Treatment of Acquired Diabetes Mellitus in People Living with Human Immunodeficiency Virus: A Review

  2021cites this paper
• Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.

  2021cites this paper
• Interactions of HIV and Antiretroviral Therapy With Neutrophils and Platelets

  2021cites this paper
• Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs

  2021cites this paper
• Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States

  2021cites this paper
• Impact of genotypic diversity on selection of subtype-specific drug resistance profiles during raltegravir-based therapy in individuals infected with B and BF recombinant HIV-1 strains.

  2020cites this paper
• Uptake and discontinuation of integrase inhibitors (INSTIs) in a large cohort setting.

  2020cites this paper
• Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

  2020cites this paper
• Harnessing cyclotides to design and develop novel peptide GPCR ligands

  2020cites this paper
• Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.

  2020cites this paper
• HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens

  2020cites this paper
• In silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main protease

  2020cites this paper
• Outcomes of Integrase Inhibitor–based Antiretroviral Therapy in a Clinical Cohort of Treatment-experienced Children, Adolescents and Young Adults With HIV Infection

  2020cites this paper
• Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

  2020cites this paper
• Recent Advances in the Development of Integrase Inhibitors for HIV Treatment

  2020cites this paper
• Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers

  2020cites this paper
• HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety

  2020cites this paper
• A novel selective histone deacetylase I inhibitor CC-4a activates latent HIV-1 through NF-κB pathway.

  2020cites this paper
• Oxadiazole-An Important Bioactive Scaffold for Drug Discovery and Development Process Against HIV and Cancer- A Review

  2019cites this paper
• Infection and Drug Resistance Dovepress

  2019cites this paper
• Antibacterial Small Molecules That Potently Inhibit Staphylococcus aureus Lipoteichoic Acid Biosynthesis

  2019cites this paper
• Update on HIV integrase inhibitors for the treatment of HIV-1 infection

  2019cites this paper
• Recent Advances towards Treatment of HIV: Synthesis and SAR Studies.

  2019cites this paper
• Devenir des personnes vivant avec le VIH sous une association TRIO dans la cohorte Aquitaine ANRS CO3 : vers une stratégie de simplification thérapeutique ?

  2019cites this paper
• Analyses of HIV‐1 integrase gene sequences among treatment‐naive patients in the Eastern Cape, South Africa

  2019cites this paper
• Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance

  2019cites this paper
• Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?

  2019cites this paper
• DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF DOLUTEGRAVIR AND RILPIVIRINE IN BULK AND PHARMACEUTICAL DOSAGE FORM AND ITS APPLICATION TO RAT PLASMA

  2019cites this paper
• Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.

  2019cites this paper
• HIV-1 integrase inhibitors targeting various DDE transposases: Retroviral integration versus RAG-mediated recombination

  2019cites this paper
• O papel do dolutegravir na terapia antiretroviral

  2019cites this paper
• Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication

  2019cites this paper
• Management of Virologic Failure and Human Immunodeficiency Virus Drug Resistance.

  2019cites this paper
• Screening Combinatorial Peptide Libraries in Protease Inhibitor Drug Discovery

  2018cites this paper
• Accumulated pre-switch resistance to more recently introduced one-pill-once-a-day antiretroviral regimens impacts HIV-1 virologic outcome.

  2018cites this paper
• Extracting functional groups of ALLINI to design derivatives of FDA‐approved drugs: Inhibition of HIV‐1 integrase

  2018cites this paper
• Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.

  2018cites this paper
• in vertically HIV-1-infected children treated rule or exception?

  2018cites this paper
• Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase

  2018cites this paper
• PR‐957, a selective immunoproteasome inhibitor, reactivates latent HIV‐1 through p‐TEFb activation mediated by HSF‐1

  2018cites this paper
• Increased dose of Dolutegravir as a Potential Rescue Therapy in Multi-Experienced Patients

  2018cites this paper
• Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patients

  2018cites this paper
• Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling

  2018cites this paper
• Patterns of Efavirenz use as First-Line Antiretroviral Therapy in the United States: 1999–2015

  2018cites this paper
• Phase 3 Study of Ibalizumab for Multidrug‐Resistant HIV‐1

  2018cites this paper
• Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation

  2018cites this paper
• Adverse drug reactions to integrase strand transfer inhibitors

  2018cites this paper
• A safety evaluation of raltegravir for the treatment of HIV

  2018cites this paper
• Prevalence and determinants of resistance mutations in HIV‐1‐infected patients exposed to integrase inhibitors in a large Italian cohort

  2018cites this paper
• Long-acting injectable ART: next revolution in HIV?

  2017cites this paper
• HIV, Immune activation and Endothelial Damage in Malawian Adults

  2017cites this paper
• Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies

  2017cites this paper
• Association of the HLA-B*53: 01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir

  2017cites this paper
• Increasing HIV-1 subtype diversity in seven states, United States, 2006-2013.

  2017cites this paper
• Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation

  2017cites this paper
• Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING

  2017cites this paper
• Synthesis, molecular modeling and biological evaluation of two new chicoric acid analogs

  2017cites this paper
• Recent Advances in Antiretroviral Agents: Potent Integrase Inhibitors.

  2017cites this paper
• Different Pathways Leading to Integrase Inhibitors Resistance

  2017cites this paper
• Continuous and discrete dynamics of a deterministic model of HIV infection

  2017cites this paper
• Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir

  2017cites this paper
• A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015

  2017cites this paper
• Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

  2017cites this paper
• Integrase-resistant HIV in an antiretroviral-naive patient in Australia.

  2017cites this paper
• Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens

  2017cites this paper
• HIV-1 molecular diversity and drug resistance mutations amongst immuno-competent, therapy naïve infants/children and adults in Yaounde, Cameroon

  2017cites this paper
• Integrase inhibitors against HIV: efficacy and resistance

  2016cites this paper
• Methods for the Analyses of Inhibitor-Induced Aberrant Multimerization of HIV-1 Integrase.

  2016cites this paper
• Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial

  2016cites this paper
• P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load

  2016cites this paper